Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at l...
Saved in:
| Published in | The Lancet (British edition) Vol. 390; no. 10099; pp. 1048 - 1060 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
09.09.2017
Elsevier Limited Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy.
IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK. Women aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocarcinoma of grade 1–3, with a tumour size of 3 cm or less (pT1–2), none to three positive axillary nodes (pN0–1), and minimum microscopic margins of non-cancerous tissue of 2 mm or more, were recruited. Patients were randomly assigned (1:1:1) to receive 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group), or 40 Gy to the partial breast only (partial-breast group) in 15 daily treatment fractions. Computer-generated random permuted blocks (mixed sizes of six and nine) were used to assign patients to groups, stratifying patients by radiotherapy treatment centre. Patients and clinicians were not masked to treatment allocation. Field-in-field intensity-modulated radiotherapy was delivered using standard tangential beams that were simply reduced in length for the partial-breast group. The primary endpoint was ipsilateral local relapse (80% power to exclude a 2·5% increase [non-inferiority margin] at 5 years for each experimental group; non-inferiority was shown if the upper limit of the two-sided 95% CI for the local relapse hazard ratio [HR] was less than 2·03), analysed by intention to treat. Safety analyses were done in all patients for whom data was available (ie, a modified intention-to-treat population). This study is registered in the ISRCTN registry, number ISRCTN12852634.
Between May 3, 2007, and Oct 5, 2010, 2018 women were recruited. Two women withdrew consent for use of their data in the analysis. 674 patients were analysed in the whole-breast radiotherapy (control) group, 673 in the reduced-dose group, and 669 in the partial-breast group. Median follow-up was 72·2 months (IQR 61·7–83·2), and 5-year estimates of local relapse cumulative incidence were 1·1% (95% CI 0·5–2·3) of patients in the control group, 0·2% (0·02–1·2) in the reduced-dose group, and 0·5% (0·2–1·4) in the partial-breast group. Estimated 5-year absolute differences in local relapse compared with the control group were −0·73% (−0·99 to 0·22) for the reduced-dose and −0·38% (−0·84 to 0·90) for the partial-breast groups. Non-inferiority can be claimed for both reduced-dose and partial-breast radiotherapy, and was confirmed by the test against the critical HR being more than 2·03 (p=0·003 for the reduced-dose group and p=0·016 for the partial-breast group, compared with the whole-breast radiotherapy group). Photographic, patient, and clinical assessments recorded similar adverse effects after reduced-dose or partial-breast radiotherapy, including two patient domains achieving statistically significantly lower adverse effects (change in breast appearance [p=0·007 for partial-breast] and breast harder or firmer [p=0·002 for reduced-dose and p<0·0001 for partial-breast]) compared with whole-breast radiotherapy.
We showed non-inferiority of partial-breast and reduced-dose radiotherapy compared with the standard whole-breast radiotherapy in terms of local relapse in a cohort of patients with early breast cancer, and equivalent or fewer late normal-tissue adverse effects were seen. This simple radiotherapy technique is implementable in radiotherapy centres worldwide.
Cancer Research UK. |
|---|---|
| AbstractList | Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy.
IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK. Women aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocarcinoma of grade 1-3, with a tumour size of 3 cm or less (pT1-2), none to three positive axillary nodes (pN0-1), and minimum microscopic margins of non-cancerous tissue of 2 mm or more, were recruited. Patients were randomly assigned (1:1:1) to receive 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group), or 40 Gy to the partial breast only (partial-breast group) in 15 daily treatment fractions. Computer-generated random permuted blocks (mixed sizes of six and nine) were used to assign patients to groups, stratifying patients by radiotherapy treatment centre. Patients and clinicians were not masked to treatment allocation. Field-in-field intensity-modulated radiotherapy was delivered using standard tangential beams that were simply reduced in length for the partial-breast group. The primary endpoint was ipsilateral local relapse (80% power to exclude a 2·5% increase [non-inferiority margin] at 5 years for each experimental group; non-inferiority was shown if the upper limit of the two-sided 95% CI for the local relapse hazard ratio [HR] was less than 2·03), analysed by intention to treat. Safety analyses were done in all patients for whom data was available (ie, a modified intention-to-treat population). This study is registered in the ISRCTN registry, number ISRCTN12852634.
Between May 3, 2007, and Oct 5, 2010, 2018 women were recruited. Two women withdrew consent for use of their data in the analysis. 674 patients were analysed in the whole-breast radiotherapy (control) group, 673 in the reduced-dose group, and 669 in the partial-breast group. Median follow-up was 72·2 months (IQR 61·7-83·2), and 5-year estimates of local relapse cumulative incidence were 1·1% (95% CI 0·5-2·3) of patients in the control group, 0·2% (0·02-1·2) in the reduced-dose group, and 0·5% (0·2-1·4) in the partial-breast group. Estimated 5-year absolute differences in local relapse compared with the control group were -0·73% (-0·99 to 0·22) for the reduced-dose and -0·38% (-0·84 to 0·90) for the partial-breast groups. Non-inferiority can be claimed for both reduced-dose and partial-breast radiotherapy, and was confirmed by the test against the critical HR being more than 2·03 (p=0·003 for the reduced-dose group and p=0·016 for the partial-breast group, compared with the whole-breast radiotherapy group). Photographic, patient, and clinical assessments recorded similar adverse effects after reduced-dose or partial-breast radiotherapy, including two patient domains achieving statistically significantly lower adverse effects (change in breast appearance [p=0·007 for partial-breast] and breast harder or firmer [p=0·002 for reduced-dose and p<0·0001 for partial-breast]) compared with whole-breast radiotherapy.
We showed non-inferiority of partial-breast and reduced-dose radiotherapy compared with the standard whole-breast radiotherapy in terms of local relapse in a cohort of patients with early breast cancer, and equivalent or fewer late normal-tissue adverse effects were seen. This simple radiotherapy technique is implementable in radiotherapy centres worldwide.
Cancer Research UK. Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy. IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK. Women aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocarcinoma of grade 1–3, with a tumour size of 3 cm or less (pT1–2), none to three positive axillary nodes (pN0–1), and minimum microscopic margins of non-cancerous tissue of 2 mm or more, were recruited. Patients were randomly assigned (1:1:1) to receive 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group), or 40 Gy to the partial breast only (partial-breast group) in 15 daily treatment fractions. Computer-generated random permuted blocks (mixed sizes of six and nine) were used to assign patients to groups, stratifying patients by radiotherapy treatment centre. Patients and clinicians were not masked to treatment allocation. Field-in-field intensity-modulated radiotherapy was delivered using standard tangential beams that were simply reduced in length for the partial-breast group. The primary endpoint was ipsilateral local relapse (80% power to exclude a 2·5% increase [non-inferiority margin] at 5 years for each experimental group; non-inferiority was shown if the upper limit of the two-sided 95% CI for the local relapse hazard ratio [HR] was less than 2·03), analysed by intention to treat. Safety analyses were done in all patients for whom data was available (ie, a modified intention-to-treat population). This study is registered in the ISRCTN registry, number ISRCTN12852634. Between May 3, 2007, and Oct 5, 2010, 2018 women were recruited. Two women withdrew consent for use of their data in the analysis. 674 patients were analysed in the whole-breast radiotherapy (control) group, 673 in the reduced-dose group, and 669 in the partial-breast group. Median follow-up was 72·2 months (IQR 61·7–83·2), and 5-year estimates of local relapse cumulative incidence were 1·1% (95% CI 0·5–2·3) of patients in the control group, 0·2% (0·02–1·2) in the reduced-dose group, and 0·5% (0·2–1·4) in the partial-breast group. Estimated 5-year absolute differences in local relapse compared with the control group were −0·73% (−0·99 to 0·22) for the reduced-dose and −0·38% (−0·84 to 0·90) for the partial-breast groups. Non-inferiority can be claimed for both reduced-dose and partial-breast radiotherapy, and was confirmed by the test against the critical HR being more than 2·03 (p=0·003 for the reduced-dose group and p=0·016 for the partial-breast group, compared with the whole-breast radiotherapy group). Photographic, patient, and clinical assessments recorded similar adverse effects after reduced-dose or partial-breast radiotherapy, including two patient domains achieving statistically significantly lower adverse effects (change in breast appearance [p=0·007 for partial-breast] and breast harder or firmer [p=0·002 for reduced-dose and p<0·0001 for partial-breast]) compared with whole-breast radiotherapy. We showed non-inferiority of partial-breast and reduced-dose radiotherapy compared with the standard whole-breast radiotherapy in terms of local relapse in a cohort of patients with early breast cancer, and equivalent or fewer late normal-tissue adverse effects were seen. This simple radiotherapy technique is implementable in radiotherapy centres worldwide. Cancer Research UK. A comprehensive literature search using PubMed and MEDLINE was done before the trial opened to identify all previous pathological and clinical breast radiotherapy studies investigating patterns of recurrence within the ipsilateral breast, and also to identify results of previous partial-breast radiotherapy studies. |
| Author | Ciurlionis, Laura Ebbs, Stephen Winstanley, John Barber, Sarah Sculpher, Mark Venables, Karen Syndikus, Isabel Mills, Judith Barnett, Gillian Provenzano, Elena James, Hayley Poynter, Andrew Griffin, Clare L Evans, Philip Harnett, Adrian N Harris, Emma Kirk, Julie Wheatley, Duncan A Bliss, Peter Sydenham, Mark Wishart, Gordon Winship, Anna Hopwood, Penelope Jefford, Monica L Kaggwa, Ronald Yarnold, John R Eaton, David Emson, Marie A Haviland, Joanne S Mayles, Helen Rawlings, Christine Agrawal, Rajiv K Tsang, Yat M Kirwan, Cliona Kirby, Anna M Twyman, Nicola Dewar, John Thompson, Alastair Tutt, Andrew Brunt, Adrian M Ellis, Ian Wilcox, Maggie Al Sarakbi, Wail Donovan, Ellen M McIntyre, Anne Bliss, Judith M Sumo, Georges Chan, Charlie Bhattacharya, Indrani S Alhasso, Abdulla Sawyer, Elinor J Coles, Charlotte E Titley, Jenny |
| AuthorAffiliation | e Department of Oncology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK f Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK b Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK a Department of Oncology, University of Cambridge, Cambridge, UK c Department of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK h Department of Radiation Oncology, Auckland City Hospital, Auckland, New Zealand p Department of Oncology, Royal Cornwall Hospitals NHS Trust, Truro, UK g Cancer Centre, University Hospitals of North Midlands and Keele University, Stoke-on-Trent, UK j Department of Health and Medical Sciences, University of Surrey, Guildford, UK m Department of Research Oncology, King's College London, London, UK n Cancer Centre, The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK l Patient Advocate, London, UK o Department of Radiotherapy, Mount Vernon Cancer Centre Northwood, Northwood, UK i Depar |
| AuthorAffiliation_xml | – name: d Department of Radiotherapy and Imaging, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK – name: i Department of Breast Surgery, Nuffield Health Cheltenham Hospital, Cheltenham, UK – name: p Department of Oncology, Royal Cornwall Hospitals NHS Trust, Truro, UK – name: k Department of Oncology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK – name: j Department of Health and Medical Sciences, University of Surrey, Guildford, UK – name: a Department of Oncology, University of Cambridge, Cambridge, UK – name: n Cancer Centre, The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK – name: o Department of Radiotherapy, Mount Vernon Cancer Centre Northwood, Northwood, UK – name: g Cancer Centre, University Hospitals of North Midlands and Keele University, Stoke-on-Trent, UK – name: h Department of Radiation Oncology, Auckland City Hospital, Auckland, New Zealand – name: c Department of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK – name: b Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – name: e Department of Oncology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK – name: f Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK – name: l Patient Advocate, London, UK – name: m Department of Research Oncology, King's College London, London, UK |
| Author_xml | – sequence: 1 givenname: Charlotte E surname: Coles fullname: Coles, Charlotte E email: colesc@doctors.org.uk organization: Department of Oncology, University of Cambridge, Cambridge, UK – sequence: 2 givenname: Clare L surname: Griffin fullname: Griffin, Clare L organization: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – sequence: 3 givenname: Anna M surname: Kirby fullname: Kirby, Anna M organization: Department of Radiotherapy and Imaging, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK – sequence: 4 givenname: Jenny surname: Titley fullname: Titley, Jenny organization: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – sequence: 5 givenname: Rajiv K surname: Agrawal fullname: Agrawal, Rajiv K organization: Department of Oncology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK – sequence: 6 givenname: Abdulla surname: Alhasso fullname: Alhasso, Abdulla organization: Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK – sequence: 7 givenname: Indrani S surname: Bhattacharya fullname: Bhattacharya, Indrani S organization: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – sequence: 8 givenname: Adrian M surname: Brunt fullname: Brunt, Adrian M organization: Cancer Centre, University Hospitals of North Midlands and Keele University, Stoke-on-Trent, UK – sequence: 9 givenname: Laura surname: Ciurlionis fullname: Ciurlionis, Laura organization: Department of Radiation Oncology, Auckland City Hospital, Auckland, New Zealand – sequence: 10 givenname: Charlie surname: Chan fullname: Chan, Charlie organization: Department of Breast Surgery, Nuffield Health Cheltenham Hospital, Cheltenham, UK – sequence: 11 givenname: Ellen M surname: Donovan fullname: Donovan, Ellen M organization: Department of Health and Medical Sciences, University of Surrey, Guildford, UK – sequence: 12 givenname: Marie A surname: Emson fullname: Emson, Marie A organization: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – sequence: 13 givenname: Adrian N surname: Harnett fullname: Harnett, Adrian N organization: Department of Oncology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK – sequence: 14 givenname: Joanne S surname: Haviland fullname: Haviland, Joanne S organization: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – sequence: 15 givenname: Penelope surname: Hopwood fullname: Hopwood, Penelope organization: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – sequence: 16 givenname: Monica L surname: Jefford fullname: Jefford, Monica L organization: Patient Advocate, London, UK – sequence: 17 givenname: Ronald surname: Kaggwa fullname: Kaggwa, Ronald organization: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – sequence: 18 givenname: Elinor J surname: Sawyer fullname: Sawyer, Elinor J organization: Department of Research Oncology, King's College London, London, UK – sequence: 19 givenname: Isabel surname: Syndikus fullname: Syndikus, Isabel organization: Cancer Centre, The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK – sequence: 20 givenname: Yat M surname: Tsang fullname: Tsang, Yat M organization: Department of Radiotherapy, Mount Vernon Cancer Centre Northwood, Northwood, UK – sequence: 21 givenname: Duncan A surname: Wheatley fullname: Wheatley, Duncan A organization: Department of Oncology, Royal Cornwall Hospitals NHS Trust, Truro, UK – sequence: 22 givenname: Maggie surname: Wilcox fullname: Wilcox, Maggie organization: Patient Advocate, London, UK – sequence: 23 givenname: John R surname: Yarnold fullname: Yarnold, John R organization: Department of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK – sequence: 24 givenname: Judith M surname: Bliss fullname: Bliss, Judith M organization: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK – sequence: 25 givenname: Wail surname: Al Sarakbi fullname: Al Sarakbi, Wail – sequence: 26 givenname: Sarah surname: Barber fullname: Barber, Sarah – sequence: 27 givenname: Gillian surname: Barnett fullname: Barnett, Gillian – sequence: 28 givenname: Peter surname: Bliss fullname: Bliss, Peter – sequence: 29 givenname: John surname: Dewar fullname: Dewar, John – sequence: 30 givenname: David surname: Eaton fullname: Eaton, David – sequence: 31 givenname: Stephen surname: Ebbs fullname: Ebbs, Stephen – sequence: 32 givenname: Ian surname: Ellis fullname: Ellis, Ian – sequence: 33 givenname: Philip surname: Evans fullname: Evans, Philip – sequence: 34 givenname: Emma surname: Harris fullname: Harris, Emma – sequence: 35 givenname: Hayley surname: James fullname: James, Hayley – sequence: 36 givenname: Cliona surname: Kirwan fullname: Kirwan, Cliona – sequence: 37 givenname: Julie surname: Kirk fullname: Kirk, Julie – sequence: 38 givenname: Helen surname: Mayles fullname: Mayles, Helen – sequence: 39 givenname: Anne surname: McIntyre fullname: McIntyre, Anne – sequence: 40 givenname: Judith surname: Mills fullname: Mills, Judith – sequence: 41 givenname: Andrew surname: Poynter fullname: Poynter, Andrew – sequence: 42 givenname: Elena surname: Provenzano fullname: Provenzano, Elena – sequence: 43 givenname: Christine surname: Rawlings fullname: Rawlings, Christine – sequence: 44 givenname: Mark surname: Sculpher fullname: Sculpher, Mark – sequence: 45 givenname: Georges surname: Sumo fullname: Sumo, Georges – sequence: 46 givenname: Mark surname: Sydenham fullname: Sydenham, Mark – sequence: 47 givenname: Andrew surname: Tutt fullname: Tutt, Andrew – sequence: 48 givenname: Nicola surname: Twyman fullname: Twyman, Nicola – sequence: 49 givenname: Karen surname: Venables fullname: Venables, Karen – sequence: 50 givenname: Anna surname: Winship fullname: Winship, Anna – sequence: 51 givenname: John surname: Winstanley fullname: Winstanley, John – sequence: 52 givenname: Gordon surname: Wishart fullname: Wishart, Gordon – sequence: 53 givenname: Alastair surname: Thompson fullname: Thompson, Alastair |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28779963$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUttu1DAQtVARvcAngCzx0kobsBM7TngAoYpLxaKtoBW8WY4z6brKxsvYuyj_yQfhvbCCJ57smTnnzNHMnJKjwQ9AyFPOXnDGy5dfGRcsK1VRnnN1UXAuZCYfkBMulMikUN-PyMkBckxOQ7hnjImSyUfkOK-UquuyOCG_rg1GZ_qsQTAhUjSt83EOaJYjNV0EpPuK9UMAXJvo_EDDCu8AR9p5pMuUgiEG-tPFOQWD_XjgmMEmhfPbT_Tq8_Xsyw2dzr7RiKnhxSsqszGhKUJY9YneoV9QQxcpcDYJIkySnaH1CxegnWwMRPR9v_kv5yYALSY0TSVzQwfoPLo47rQfk4ed6QM82b9n5Pb9u5vLj9l09uHq8u00s2lAMYOu4QwYdGUnc8kabq1thaikEaauweaVMSlSrShEUzRS5RZ4xbrOQpUbBsUZeb3TXa6aBbRb06bXS3QLg6P2xul_K4Ob6zu_1lLWIhcqCTzfC6D_sYIQ9b1f4ZA8a14XSpWqrKqEkjuURR8CQnfowJneHIPeHoPebFpzpbfHoGXiPfvb3oH1Z_sJ8GYHgDSktQPUwaZVWmgdgo269e4_LX4DNh3MGg |
| CitedBy_id | crossref_primary_10_1093_bjr_tqae028 crossref_primary_10_3390_cancers16020270 crossref_primary_10_1007_s10549_019_05209_9 crossref_primary_10_1016_j_ejca_2019_11_024 crossref_primary_10_7759_cureus_28223 crossref_primary_10_3390_curroncol30010015 crossref_primary_10_1016_j_clon_2020_01_025 crossref_primary_10_1186_s13014_019_1308_y crossref_primary_10_1186_s13014_024_02412_x crossref_primary_10_1001_jamaoncol_2020_7468 crossref_primary_10_1016_j_jgo_2020_07_013 crossref_primary_10_1186_s13014_020_01581_9 crossref_primary_10_1186_s13014_020_01713_1 crossref_primary_10_1007_s12282_019_01009_7 crossref_primary_10_1245_s10434_023_13665_3 crossref_primary_10_1007_s10549_020_06086_3 crossref_primary_10_1016_j_intimp_2024_111549 crossref_primary_10_1016_j_prro_2024_04_024 crossref_primary_10_1016_j_ijrobp_2022_09_062 crossref_primary_10_1200_JCO_20_02768 crossref_primary_10_1097_SLA_0000000000005064 crossref_primary_10_1200_JCO_20_03613 crossref_primary_10_1016_S0140_6736_17_33317_2 crossref_primary_10_1007_s00129_019_04532_y crossref_primary_10_1016_j_ijrobp_2019_02_050 crossref_primary_10_1080_0284186X_2017_1408962 crossref_primary_10_1016_j_ctro_2022_09_004 crossref_primary_10_1038_s41523_023_00591_6 crossref_primary_10_3390_curroncol30010032 crossref_primary_10_1016_j_cson_2023_100010 crossref_primary_10_1016_j_ejso_2024_108058 crossref_primary_10_1016_j_clon_2019_05_008 crossref_primary_10_1016_j_ijrobp_2020_06_064 crossref_primary_10_1016_j_ctro_2022_10_008 crossref_primary_10_1016_S0140_6736_19_32959_9 crossref_primary_10_3389_fonc_2021_738318 crossref_primary_10_1007_s11547_022_01563_9 crossref_primary_10_1002_jmrs_590 crossref_primary_10_1016_j_breast_2020_10_010 crossref_primary_10_1007_s00404_021_06015_9 crossref_primary_10_1016_j_critrevonc_2022_103774 crossref_primary_10_1186_s13014_018_1119_6 crossref_primary_10_1016_j_prro_2021_06_012 crossref_primary_10_1016_j_rpor_2019_01_009 crossref_primary_10_1007_s12609_021_00411_5 crossref_primary_10_1016_j_adro_2023_101403 crossref_primary_10_1007_s10549_023_06899_y crossref_primary_10_1097_COC_0000000000000970 crossref_primary_10_1016_j_clbc_2023_12_012 crossref_primary_10_1111_ajco_13462 crossref_primary_10_1016_j_ijrobp_2019_03_050 crossref_primary_10_1007_s10555_018_9761_x crossref_primary_10_1007_s13566_017_0338_z crossref_primary_10_1200_JCO_20_00650 crossref_primary_10_1007_s12609_020_00384_x crossref_primary_10_1016_S0140_6736_20_30932_6 crossref_primary_10_1155_2022_1734049 crossref_primary_10_1038_nrclinonc_2017_139 crossref_primary_10_1016_j_brachy_2021_08_009 crossref_primary_10_1186_s13058_021_01424_9 crossref_primary_10_1016_j_esmoop_2024_102974 crossref_primary_10_1016_j_ijrobp_2021_05_004 crossref_primary_10_1016_j_ejso_2022_03_017 crossref_primary_10_1200_JCO_23_02289 crossref_primary_10_1016_j_lansea_2024_100392 crossref_primary_10_1016_j_brachy_2020_06_018 crossref_primary_10_1016_j_brachy_2022_08_005 crossref_primary_10_1016_j_ijrobp_2020_04_041 crossref_primary_10_1016_j_ijrobp_2023_10_016 crossref_primary_10_1093_jnci_djad100 crossref_primary_10_1016_j_clon_2019_04_010 crossref_primary_10_1016_j_ctro_2020_12_005 crossref_primary_10_1111_tbj_13827 crossref_primary_10_1155_2021_7462012 crossref_primary_10_1016_j_prro_2022_01_006 crossref_primary_10_1016_S0140_6736_17_31599_4 crossref_primary_10_1016_S1470_2045_21_00080_2 crossref_primary_10_1007_s00066_020_01744_3 crossref_primary_10_3389_fonc_2023_1354731 crossref_primary_10_1007_s12609_024_00544_3 crossref_primary_10_5306_wjco_v11_i1_20 crossref_primary_10_1007_s00432_023_04973_y crossref_primary_10_1016_j_annonc_2023_11_016 crossref_primary_10_1001_jamasurg_2022_0631 crossref_primary_10_1371_journal_pone_0237658 crossref_primary_10_1007_s15015_018_3739_y crossref_primary_10_1016_j_jddst_2020_102312 crossref_primary_10_3389_pore_2022_1610378 crossref_primary_10_1016_j_prro_2023_10_009 crossref_primary_10_1259_bjr_20220707 crossref_primary_10_3390_curroncol30010088 crossref_primary_10_1186_s13014_021_01752_2 crossref_primary_10_1007_s00066_020_01613_z crossref_primary_10_1016_S0140_6736_23_00619_0 crossref_primary_10_1016_j_adro_2021_100701 crossref_primary_10_1177_1457496920903975 crossref_primary_10_1016_j_ijrobp_2022_09_083 crossref_primary_10_1016_j_prro_2020_03_011 crossref_primary_10_1002_cam4_5007 crossref_primary_10_1097_COC_0000000000000945 crossref_primary_10_3390_genes13060960 crossref_primary_10_1007_s10549_022_06853_4 crossref_primary_10_1055_a_1942_5061 crossref_primary_10_1007_s12094_020_02319_5 crossref_primary_10_1136_bmjopen_2023_075543 crossref_primary_10_1016_j_radonc_2021_03_029 crossref_primary_10_1159_000488189 crossref_primary_10_1200_JCO_22_01751 crossref_primary_10_1007_s00129_022_04933_6 crossref_primary_10_1016_j_ijrobp_2021_05_110 crossref_primary_10_1016_j_rpor_2019_09_004 crossref_primary_10_3389_fonc_2022_1049704 crossref_primary_10_1007_s12032_018_1121_8 crossref_primary_10_3390_cancers15041260 crossref_primary_10_1016_j_adro_2021_100731 crossref_primary_10_1155_2020_8309492 crossref_primary_10_1016_j_ejso_2022_08_021 crossref_primary_10_1016_j_critrevonc_2023_104035 crossref_primary_10_1159_000500847 crossref_primary_10_1200_JCO_20_01397 crossref_primary_10_1001_jamaoncol_2020_0795 crossref_primary_10_3390_cancers14041066 crossref_primary_10_1245_s10434_022_12193_w crossref_primary_10_1007_s00432_020_03152_7 crossref_primary_10_1111_tbj_13193 crossref_primary_10_2217_bmt_2018_0001 crossref_primary_10_1007_s10549_021_06314_4 crossref_primary_10_1016_j_prro_2019_09_007 crossref_primary_10_1200_JCO_19_02594 crossref_primary_10_3390_curroncol29100552 crossref_primary_10_1016_j_clon_2021_01_012 crossref_primary_10_1002_pro6_1208 crossref_primary_10_1093_ageing_afz089 crossref_primary_10_35366_101727 crossref_primary_10_61409_V02230106 crossref_primary_10_1038_s41598_020_68035_w crossref_primary_10_1200_JCO_20_00070 crossref_primary_10_3390_cancers12082309 crossref_primary_10_1016_j_brachy_2020_11_002 crossref_primary_10_1155_2018_8321871 crossref_primary_10_1016_j_brachy_2022_07_004 crossref_primary_10_1016_j_phro_2022_02_001 crossref_primary_10_1016_j_ctro_2022_11_015 crossref_primary_10_1159_000506254 crossref_primary_10_1016_j_breast_2017_12_014 crossref_primary_10_3390_cancers13122967 crossref_primary_10_1007_s12282_024_01546_w crossref_primary_10_1007_s12094_021_02636_3 crossref_primary_10_1016_j_radonc_2019_01_036 crossref_primary_10_1097_PPO_0000000000000496 crossref_primary_10_3390_cancers15174343 crossref_primary_10_1136_bmj_m2836 crossref_primary_10_1016_j_prro_2023_11_001 crossref_primary_10_1016_j_prro_2022_05_010 crossref_primary_10_1200_JCO_22_00451 crossref_primary_10_1016_S1470_2045_20_30741_5 crossref_primary_10_1016_j_radonc_2021_06_021 crossref_primary_10_3310_WWBF1044 crossref_primary_10_1186_s13014_019_1364_3 crossref_primary_10_1016_j_ijrobp_2018_09_021 crossref_primary_10_1016_j_prro_2018_08_003 crossref_primary_10_1016_S1470_2045_23_00062_1 crossref_primary_10_1016_j_ijrobp_2023_12_026 crossref_primary_10_1097_SP9_0000000000000018 crossref_primary_10_1111_tbj_13164 crossref_primary_10_1016_j_adro_2021_100752 crossref_primary_10_1186_s13014_018_1079_x crossref_primary_10_1016_j_adro_2021_100654 crossref_primary_10_1016_j_clon_2024_06_045 crossref_primary_10_1016_j_ijrobp_2020_02_021 crossref_primary_10_1007_s15004_018_6157_6 crossref_primary_10_1016_j_brachy_2022_06_002 crossref_primary_10_1016_j_clbc_2020_12_007 crossref_primary_10_1016_j_ijrobp_2022_12_036 crossref_primary_10_1016_j_rpor_2020_07_008 crossref_primary_10_1259_bjr_20180908 crossref_primary_10_1016_S1470_2045_18_30195_5 crossref_primary_10_1016_j_radonc_2021_11_001 crossref_primary_10_3390_cancers15010298 crossref_primary_10_1200_JCO_22_01485 crossref_primary_10_18632_aging_202355 crossref_primary_10_1002_jmrs_453 crossref_primary_10_1007_s00066_018_1378_z crossref_primary_10_1016_j_ijrobp_2021_10_014 crossref_primary_10_1200_JCO_19_02795 crossref_primary_10_1245_s10434_019_07350_7 crossref_primary_10_1007_s00066_019_01472_3 crossref_primary_10_1186_s12885_023_10910_6 crossref_primary_10_1093_jrr_rry095 crossref_primary_10_1016_S0960_9776_19_31128_2 crossref_primary_10_1055_a_1103_3066 crossref_primary_10_1007_s11547_023_01743_1 crossref_primary_10_1016_S0140_6736_20_32381_3 crossref_primary_10_1016_j_canrad_2019_06_004 crossref_primary_10_1007_s12609_023_00497_z crossref_primary_10_1016_j_radonc_2021_11_019 crossref_primary_10_1007_s00066_022_01998_z crossref_primary_10_1007_s12609_019_00326_2 crossref_primary_10_1007_s10549_020_05781_5 crossref_primary_10_1159_000513708 crossref_primary_10_1007_s11547_020_01147_5 crossref_primary_10_1016_S0140_6736_17_33316_0 crossref_primary_10_1016_j_prro_2023_12_003 crossref_primary_10_1016_j_ijrobp_2023_08_065 crossref_primary_10_1016_j_ijrobp_2023_08_062 crossref_primary_10_1016_j_radonc_2020_03_004 crossref_primary_10_1016_j_brachy_2020_03_003 crossref_primary_10_1016_j_breast_2024_103759 crossref_primary_10_1016_j_clon_2022_02_009 crossref_primary_10_1007_s12094_021_02618_5 crossref_primary_10_1007_s12094_022_02821_y crossref_primary_10_1016_j_breast_2023_03_013 crossref_primary_10_1016_j_clbc_2021_05_015 crossref_primary_10_1159_000515386 crossref_primary_10_1016_j_breast_2023_103584 crossref_primary_10_3389_fonc_2021_617439 crossref_primary_10_3389_fonc_2023_1275222 crossref_primary_10_1155_2022_6745954 crossref_primary_10_1093_annonc_mdz173 crossref_primary_10_1016_j_brachy_2017_09_004 crossref_primary_10_1016_j_radonc_2019_11_025 crossref_primary_10_1016_j_breast_2023_03_009 crossref_primary_10_1016_j_jgo_2021_05_008 crossref_primary_10_1016_j_radonc_2023_110066 crossref_primary_10_1016_S0140_6736_19_32514_0 crossref_primary_10_1002_cai2_106 crossref_primary_10_1016_j_brachy_2017_09_009 crossref_primary_10_1007_s00066_021_01848_4 crossref_primary_10_1007_s12094_021_02729_z crossref_primary_10_1016_j_radonc_2024_110217 crossref_primary_10_1016_j_breast_2019_09_009 crossref_primary_10_1111_jcmm_15367 crossref_primary_10_1016_j_canrad_2023_04_002 crossref_primary_10_1088_1361_6560_ac5ce5 crossref_primary_10_1016_j_radonc_2024_110336 crossref_primary_10_1016_j_critrevonc_2019_02_014 crossref_primary_10_1016_j_brachy_2020_10_010 crossref_primary_10_1016_j_radonc_2023_110076 crossref_primary_10_1016_j_brachy_2019_05_002 crossref_primary_10_1245_s10434_023_13233_9 crossref_primary_10_1097_MD_0000000000024098 crossref_primary_10_1016_j_brachy_2020_10_005 crossref_primary_10_1080_23808993_2021_1897463 crossref_primary_10_1007_s12609_023_00499_x crossref_primary_10_1016_S1470_2045_21_00120_0 crossref_primary_10_2147_BCTT_S432526 crossref_primary_10_1016_j_ctro_2018_11_003 crossref_primary_10_1016_j_radonc_2021_01_003 crossref_primary_10_3389_fonc_2023_1118713 crossref_primary_10_1016_j_clon_2019_09_061 crossref_primary_10_1016_S0140_6736_19_32515_2 crossref_primary_10_1016_j_radonc_2023_110045 crossref_primary_10_1016_j_ijrobp_2020_07_2312 crossref_primary_10_1007_s12032_021_01514_w crossref_primary_10_1016_j_breast_2020_04_006 crossref_primary_10_3390_jpm12040653 crossref_primary_10_1007_s00066_022_01930_5 crossref_primary_10_1038_s41416_018_0201_z crossref_primary_10_1016_j_canrad_2021_08_004 crossref_primary_10_1245_s10434_020_08450_5 crossref_primary_10_1002_pro6_1183 crossref_primary_10_1136_ebmed_2017_110849 crossref_primary_10_1001_jamaoncol_2020_0249 crossref_primary_10_1007_s15004_017_5891_5 crossref_primary_10_1016_j_prro_2021_08_009 crossref_primary_10_1007_s12094_022_02823_w crossref_primary_10_2298_SARH200422010I crossref_primary_10_1016_S1470_2045_23_00018_9 crossref_primary_10_1007_s12312_019_0637_y crossref_primary_10_1016_j_radonc_2022_09_024 crossref_primary_10_1097_MD_0000000000019916 crossref_primary_10_1200_JCO_19_02388 crossref_primary_10_1186_s13014_020_01501_x crossref_primary_10_1016_j_radonc_2020_06_041 crossref_primary_10_3389_fonc_2023_1195266 crossref_primary_10_1016_j_esmoop_2022_100605 crossref_primary_10_1016_j_radonc_2022_10_025 crossref_primary_10_1016_j_breast_2023_04_006 crossref_primary_10_1016_j_breast_2023_04_007 crossref_primary_10_1016_j_radonc_2022_10_021 crossref_primary_10_1186_s13014_023_02365_7 crossref_primary_10_1002_cac2_12358 crossref_primary_10_1016_j_ctro_2021_04_005 crossref_primary_10_1016_j_brachy_2017_11_008 crossref_primary_10_1007_s15004_019_6522_0 crossref_primary_10_3390_cancers15123128 crossref_primary_10_1038_s41416_020_01233_5 crossref_primary_10_1016_j_suc_2022_08_015 crossref_primary_10_3390_cancers13235928 crossref_primary_10_1259_bjr_20170849 crossref_primary_10_1016_j_ijrobp_2023_05_018 crossref_primary_10_1016_j_brachy_2021_02_003 crossref_primary_10_1016_j_radonc_2022_11_017 crossref_primary_10_1016_j_brachy_2019_04_003 crossref_primary_10_1016_S1470_2045_23_00095_5 crossref_primary_10_1016_j_clbc_2020_09_004 crossref_primary_10_1016_j_ijrobp_2022_03_010 crossref_primary_10_1016_j_radonc_2022_10_009 crossref_primary_10_12688_f1000research_21151_1 crossref_primary_10_1016_j_canrad_2022_04_003 crossref_primary_10_1016_j_critrevonc_2020_102967 crossref_primary_10_1016_j_ijrobp_2018_12_025 crossref_primary_10_1001_jama_2018_19323 crossref_primary_10_1016_j_clbc_2020_04_003 crossref_primary_10_1016_j_soc_2023_03_002 crossref_primary_10_1016_j_ijrobp_2020_10_009 crossref_primary_10_1016_j_ijrobp_2021_01_015 crossref_primary_10_1007_s00066_020_01609_9 crossref_primary_10_1016_j_ijrobp_2019_11_406 crossref_primary_10_1016_j_semradonc_2022_01_012 crossref_primary_10_1016_S1470_2045_21_00539_8 crossref_primary_10_1016_j_semradonc_2022_01_010 crossref_primary_10_1111_tbj_13241 crossref_primary_10_3389_fonc_2020_01107 crossref_primary_10_1055_a_2256_3983 crossref_primary_10_1016_j_ctro_2018_09_001 crossref_primary_10_1200_JCO_20_01703 crossref_primary_10_1007_s10549_022_06802_1 crossref_primary_10_1016_j_ctro_2024_100745 crossref_primary_10_1016_j_hoc_2019_08_014 crossref_primary_10_1016_j_brachy_2020_07_010 crossref_primary_10_1016_j_adro_2019_09_005 crossref_primary_10_3389_fonc_2021_649301 crossref_primary_10_1200_JCO_18_00982 crossref_primary_10_3390_curroncol31030121 crossref_primary_10_1016_j_ijrobp_2018_05_028 crossref_primary_10_1002_14651858_CD007077_pub4 crossref_primary_10_1007_s10549_023_07112_w crossref_primary_10_1016_S0140_6736_23_02698_3 crossref_primary_10_1007_s00761_019_0628_8 crossref_primary_10_1055_a_1826_2992 crossref_primary_10_4048_jbc_2023_0296 crossref_primary_10_1007_s12094_021_02664_z crossref_primary_10_1016_j_ijrobp_2019_11_024 crossref_primary_10_1007_s12609_021_00414_2 crossref_primary_10_1016_j_adro_2023_101263 crossref_primary_10_1016_j_clon_2022_06_006 crossref_primary_10_1007_s00066_021_01839_5 crossref_primary_10_1016_j_brachy_2021_01_002 crossref_primary_10_1016_j_clon_2021_04_016 crossref_primary_10_1016_j_radonc_2022_01_010 crossref_primary_10_1007_s00066_017_1202_1 crossref_primary_10_1016_j_senol_2020_04_002 crossref_primary_10_1200_OP_21_00635 crossref_primary_10_1016_j_clinimag_2021_06_035 crossref_primary_10_1097_COC_0000000000000584 crossref_primary_10_3390_jpm12071116 crossref_primary_10_1016_j_adro_2020_10_018 crossref_primary_10_1016_j_clon_2018_08_007 crossref_primary_10_1007_s10549_019_05304_x crossref_primary_10_3390_biomedicines11010098 crossref_primary_10_1016_j_radonc_2024_110193 crossref_primary_10_1016_j_radonc_2024_110195 crossref_primary_10_1016_j_ijrobp_2020_11_006 crossref_primary_10_1016_j_ctro_2022_08_013 crossref_primary_10_1007_s10549_023_07190_w crossref_primary_10_1007_s11864_020_00782_4 crossref_primary_10_1016_j_breast_2019_04_006 crossref_primary_10_1016_j_ijrobp_2020_06_041 crossref_primary_10_1016_j_adro_2022_101111 crossref_primary_10_1002_cncr_33422 crossref_primary_10_1016_j_adro_2023_101233 crossref_primary_10_1016_j_brachy_2023_04_007 crossref_primary_10_1186_s13014_019_1448_0 crossref_primary_10_1080_0284186X_2019_1643915 crossref_primary_10_6004_jnccn_2022_0030 crossref_primary_10_1007_s13566_018_0359_2 crossref_primary_10_1007_s40944_024_00821_0 crossref_primary_10_1016_j_senol_2023_100504 crossref_primary_10_1016_j_ijrobp_2019_12_037 crossref_primary_10_3389_fonc_2020_550950 crossref_primary_10_1080_0284186X_2018_1481294 crossref_primary_10_1001_jamadermatol_2022_1736 crossref_primary_10_3389_fonc_2023_1146754 crossref_primary_10_1259_bjr_20170565 crossref_primary_10_1186_s13058_022_01582_4 crossref_primary_10_1016_j_brachy_2019_06_002 crossref_primary_10_1016_j_radonc_2018_11_006 crossref_primary_10_21294_1814_4861_2022_21_1_99_106 crossref_primary_10_1007_s00066_021_01808_y crossref_primary_10_1016_j_canrad_2021_11_013 crossref_primary_10_1016_j_adro_2020_03_013 crossref_primary_10_1016_j_phro_2022_06_015 crossref_primary_10_1016_j_prro_2019_04_002 crossref_primary_10_1097_COC_0000000000000542 crossref_primary_10_1007_s00066_024_02203_z crossref_primary_10_1016_j_clon_2020_03_006 crossref_primary_10_1111_tbj_13767 crossref_primary_10_1007_s00129_024_05215_z |
| Cites_doi | 10.1056/NEJMoa1415369 10.1016/j.radonc.2016.12.021 10.1016/j.clon.2017.06.011 10.1097/SLA.0000000000001863 10.1016/S1470-2045(13)70035-4 10.1200/JCO.2013.49.7842 10.1016/j.ejso.2008.09.005 10.1056/NEJMoa1415340 10.1016/S1470-2045(13)70497-2 10.1016/S1470-2045(13)70386-3 10.1016/j.radonc.2010.05.014 10.1118/1.4748332 10.1093/annonc/mdu561 10.1007/s00066-013-0437-8 10.1016/j.brachy.2013.02.001 10.1046/j.1365-2168.1999.00961.x 10.1200/JCO.2013.50.5511 10.1016/S0140-6736(13)61950-9 10.1016/S0140-6736(15)00471-7 10.1016/j.clon.2016.01.011 10.1016/j.radonc.2005.01.005 10.1016/j.clon.2012.11.003 10.1016/j.semradonc.2010.08.007 10.1016/j.ijrobp.2012.10.010 10.1016/S0140-6736(11)61629-2 10.1016/j.radonc.2014.11.014 10.1016/j.ejca.2014.12.013 10.1111/1754-9485.12348 10.1016/j.clon.2008.03.017 10.1016/j.ijrobp.2009.02.031 10.1016/j.radonc.2008.05.002 10.1016/j.radonc.2010.01.014 10.1016/j.radonc.2010.01.019 10.1016/j.ijrobp.2008.10.030 10.1016/j.ejso.2013.07.240 |
| ContentType | Journal Article |
| Contributor | Ebbs, Stephen Winstanley, John Barber, Sarah Sculpher, Mark Mayles, Helen Venables, Karen Rawlings, Christine Mills, Judith Barnett, Gillian Provenzano, Elena James, Hayley Kirwan, Cliona Poynter, Andrew Twyman, Nicola Dewar, John Evans, Philip Thompson, Alastair Harris, Emma Tutt, Andrew Kirk, Julie Ellis, Ian Al Sarakbi, Wail Bliss, Peter Sydenham, Mark Wishart, Gordon McIntyre, Anne Winship, Anna Sumo, Georges Eaton, David |
| Contributor_xml | – sequence: 1 givenname: Wail surname: Al Sarakbi fullname: Al Sarakbi, Wail – sequence: 2 givenname: Sarah surname: Barber fullname: Barber, Sarah – sequence: 3 givenname: Gillian surname: Barnett fullname: Barnett, Gillian – sequence: 4 givenname: Peter surname: Bliss fullname: Bliss, Peter – sequence: 5 givenname: John surname: Dewar fullname: Dewar, John – sequence: 6 givenname: David surname: Eaton fullname: Eaton, David – sequence: 7 givenname: Stephen surname: Ebbs fullname: Ebbs, Stephen – sequence: 8 givenname: Ian surname: Ellis fullname: Ellis, Ian – sequence: 9 givenname: Philip surname: Evans fullname: Evans, Philip – sequence: 10 givenname: Emma surname: Harris fullname: Harris, Emma – sequence: 11 givenname: Hayley surname: James fullname: James, Hayley – sequence: 12 givenname: Cliona surname: Kirwan fullname: Kirwan, Cliona – sequence: 13 givenname: Julie surname: Kirk fullname: Kirk, Julie – sequence: 14 givenname: Helen surname: Mayles fullname: Mayles, Helen – sequence: 15 givenname: Anne surname: McIntyre fullname: McIntyre, Anne – sequence: 16 givenname: Judith surname: Mills fullname: Mills, Judith – sequence: 17 givenname: Andrew surname: Poynter fullname: Poynter, Andrew – sequence: 18 givenname: Elena surname: Provenzano fullname: Provenzano, Elena – sequence: 19 givenname: Christine surname: Rawlings fullname: Rawlings, Christine – sequence: 20 givenname: Mark surname: Sculpher fullname: Sculpher, Mark – sequence: 21 givenname: Georges surname: Sumo fullname: Sumo, Georges – sequence: 22 givenname: Mark surname: Sydenham fullname: Sydenham, Mark – sequence: 23 givenname: Andrew surname: Tutt fullname: Tutt, Andrew – sequence: 24 givenname: Nicola surname: Twyman fullname: Twyman, Nicola – sequence: 25 givenname: Karen surname: Venables fullname: Venables, Karen – sequence: 26 givenname: Anna surname: Winship fullname: Winship, Anna – sequence: 27 givenname: John surname: Winstanley fullname: Winstanley, John – sequence: 28 givenname: Gordon surname: Wishart fullname: Wishart, Gordon – sequence: 29 givenname: Alastair surname: Thompson fullname: Thompson, Alastair |
| Copyright | 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Sep 9, 2017 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2017 |
| Copyright_xml | – notice: 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Sep 9, 2017 – notice: 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2017 |
| CorporateAuthor | IMPORT Trialists |
| CorporateAuthor_xml | – name: IMPORT Trialists |
| DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TT 0TZ 0U~ 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PQEST PQQKQ PQUKI PRINS PSYQQ Q9U S0X 5PM |
| DOI | 10.1016/S0140-6736(17)31145-5 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef News PRO Pharma and Biotech Premium PRO Global News & ABI/Inform Professional ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional ProQuest Biological Science Collection Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Psychology Research Library Prep ProQuest Central Student News PRO ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management Global News & ABI/Inform Professional Health Research Premium Collection Natural Science Collection Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts Pharma and Biotech Premium PRO SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) |
| DatabaseTitleList | MEDLINE ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 1060 |
| ExternalDocumentID | 10_1016_S0140_6736_17_31145_5 28779963 S0140673617311455 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Journal Article |
| GrantInformation | Cancer Research UK. |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_PC_14105 – fundername: Cancer Research UK grantid: 10588 – fundername: Cancer Research UK grantid: 19727 – fundername: Cancer Research UK grantid: 6035 – fundername: Department of Health grantid: NIHR-CS-011-014 – fundername: Cancer Research UK grantid: 21752 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 04C 0R~ 123 1B1 1P~ 1RT 1~5 29L 3V. 4.4 457 4G. 53G 5VS 6I. 7-5 71M 7RV 7X7 88A 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AACTN AAEDT AAEDW AAFTH AAIKJ AAKOC AALRI AAQFI AAQQT AAXUO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABLVK ABMAC ABMZM ABOCM ABUWG ABYKQ ACGFS ACGOD ACIUM ACPRK ACRLP ADBBV AEKER AENEX AEVXI AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHMBA AHPSJ AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AN0 ANZVX AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0L M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PQQKQ PRG PROAC PSQYO PSYQQ R2- RIG ROL RPZ S0X SAD SDF SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU XFK YYM Z5R ZA5 ZMT AFCTW AKRWK ALIPV CGR CUY CVF ECM EIF NPM .GJ 3EH 3O- 41~ 8WZ A6W AAEJM AAKAS AAQXK AAXKI AAYOK AAYXX ABDBF ABTAH ACRZS ADMUD ADZCM AFFNX AHHHB AJJEV AKVCP ARTTT ASPBG AVWKF AZFZN CITATION D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H MVM OVD Q~Q SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 0TT 0TZ 0U~ 7QL 7QP 7TK 7U7 7U9 7XB 8FK AAMRU ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PQEST PQUKI PRINS Q9U 5PM |
| ID | FETCH-LOGICAL-c547t-efb10e0ef6f5250b1cccd4485a4a99ec28aa4857d434b3b572ce180ffce82a0e3 |
| IEDL.DBID | BENPR |
| ISSN | 0140-6736 |
| IngestDate | Tue Sep 17 21:08:29 EDT 2024 Tue Sep 24 23:04:39 EDT 2024 Thu Sep 12 17:29:50 EDT 2024 Sun Jun 23 00:34:26 EDT 2024 Fri Feb 23 02:34:53 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10099 |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c547t-efb10e0ef6f5250b1cccd4485a4a99ec28aa4857d434b3b572ce180ffce82a0e3 |
| Notes | Members listed in the appendix pp 90–92 Contributed equally |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC5594247 |
| PMID | 28779963 |
| PQID | 1937767688 |
| PQPubID | 40246 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5594247 proquest_journals_1937767688 crossref_primary_10_1016_S0140_6736_17_31145_5 pubmed_primary_28779963 elsevier_sciencedirect_doi_10_1016_S0140_6736_17_31145_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-09 |
| PublicationDateYYYYMMDD | 2017-09-09 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-09 day: 09 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd Elsevier Limited Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Elsevier |
| References | Vaidya, Wenz, Bulsara (bib31) 2014; 383 Shah, Vicini, Wazer, Arthur, Patel (bib10) 2013; 12 Salvadori, Marubini, Miceli (bib12) 1999; 86 Veronesi, Orecchia, Maisonneuve (bib23) 2013; 14 Marta, Macedo, Carvalho Hde, Hanna, da Silva, Riera (bib17) 2015; 114 Bloomfield (bib32) 2017 Polgár, Van Limbergen, Pötter (bib8) 2010; 94 Schaverien, Stallard, Dodwell, Doughty (bib20) 2013; 39 Haviland, Ashton, Broad (bib22) 2008; 20 Kirby, Evans, Donovan, Convery, Haviland, Yarnold (bib28) 2010; 96 Mukesh, Barnett, Wilkinson (bib30) 2013; 31 Coles, Donovan, Haviland, Yarnold (bib15) 2013; 25 (bib1) 2011; 378 Strnad, Ott, Hildebrandt (bib18) 2016; 387 Poortmans, Collette, Kirkove (bib36) 2015; 373 Smith, Arthur, Buchholz (bib6) 2009; 74 Belkacemi, Kaidar-Person, Poortmans (bib4) 2015; 26 Livi, Meattini, Marrazzo (bib24) 2015; 51 Haviland, Hopwood, Mills, Sydenham, Bliss, Yarnold (bib26) 2016; 28 Whelan, Olivotto, Parulekar (bib35) 2015; 373 Dundas, Pogson, Batumalai (bib5) 2015; 59 Hickey, Lehman, Francis, See (bib37) 2016; 7 Wilkinson, Beitsch, Shah (bib9) 2013; 85 Donovan, James, Bonora, Yarnold, Evans (bib27) 2012; 39 Galimberti, Cole, Zurrida (bib34) 2013; 14 Mannino, Yarnold (bib11) 2009; 90 Coles, Wilson, Cumming (bib13) 2009; 35 Haviland, Owen, Dewar (bib19) 2013; 14 Théberge, Whelan, Shaitelman, Vicini (bib16) 2011; 21 (bib2) 1998; 158 Olivotto, Whelan, Parpia (bib25) 2013; 31 Polgár, Major, Fodor (bib7) 2010; 94 Yarnold, Ashton, Bliss (bib21) 2005; 75 Sedlmayer, Sautter-Bihl, Budach (bib3) 2013; 189 Gentilini, Botteri, Leonardi (bib29) 2017; 122 Harris, Donovan, Yarnold, Coles, Evans (bib14) 2009; 73 Giuliano, Ballman, McCall (bib33) 2016; 264 28895573 - Nat Rev Clin Oncol. 2017 Oct;14(10):585 29323648 - Lancet. 2018 Jan 6;391(10115):26-27 29323651 - Lancet. 2018 Jan 6;391(10115):27-28 33220220 - Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1123-1128 28779962 - Lancet. 2017 Sep 9;390(10099):1010-1012 29289822 - Breast. 2018 Apr;38:98-100 29367327 - BMJ Evid Based Med. 2018 Feb;23(1):38-39 Veronesi (10.1016/S0140-6736(17)31145-5_bib23) 2013; 14 (10.1016/S0140-6736(17)31145-5_bib1) 2011; 378 Dundas (10.1016/S0140-6736(17)31145-5_bib5) 2015; 59 Salvadori (10.1016/S0140-6736(17)31145-5_bib12) 1999; 86 Coles (10.1016/S0140-6736(17)31145-5_bib13) 2009; 35 Shah (10.1016/S0140-6736(17)31145-5_bib10) 2013; 12 Mannino (10.1016/S0140-6736(17)31145-5_bib11) 2009; 90 Haviland (10.1016/S0140-6736(17)31145-5_bib26) 2016; 28 Marta (10.1016/S0140-6736(17)31145-5_bib17) 2015; 114 Schaverien (10.1016/S0140-6736(17)31145-5_bib20) 2013; 39 Bloomfield (10.1016/S0140-6736(17)31145-5_bib32) 2017 Poortmans (10.1016/S0140-6736(17)31145-5_bib36) 2015; 373 Théberge (10.1016/S0140-6736(17)31145-5_bib16) 2011; 21 Smith (10.1016/S0140-6736(17)31145-5_bib6) 2009; 74 Strnad (10.1016/S0140-6736(17)31145-5_bib18) 2016; 387 Donovan (10.1016/S0140-6736(17)31145-5_bib27) 2012; 39 Haviland (10.1016/S0140-6736(17)31145-5_bib19) 2013; 14 Polgár (10.1016/S0140-6736(17)31145-5_bib7) 2010; 94 Whelan (10.1016/S0140-6736(17)31145-5_bib35) 2015; 373 Harris (10.1016/S0140-6736(17)31145-5_bib14) 2009; 73 Wilkinson (10.1016/S0140-6736(17)31145-5_bib9) 2013; 85 Livi (10.1016/S0140-6736(17)31145-5_bib24) 2015; 51 (10.1016/S0140-6736(17)31145-5_bib2) 1998; 158 Giuliano (10.1016/S0140-6736(17)31145-5_bib33) 2016; 264 Galimberti (10.1016/S0140-6736(17)31145-5_bib34) 2013; 14 Belkacemi (10.1016/S0140-6736(17)31145-5_bib4) 2015; 26 Coles (10.1016/S0140-6736(17)31145-5_bib15) 2013; 25 Haviland (10.1016/S0140-6736(17)31145-5_bib22) 2008; 20 Olivotto (10.1016/S0140-6736(17)31145-5_bib25) 2013; 31 Vaidya (10.1016/S0140-6736(17)31145-5_bib31) 2014; 383 Sedlmayer (10.1016/S0140-6736(17)31145-5_bib3) 2013; 189 Polgár (10.1016/S0140-6736(17)31145-5_bib8) 2010; 94 Mukesh (10.1016/S0140-6736(17)31145-5_bib30) 2013; 31 Yarnold (10.1016/S0140-6736(17)31145-5_bib21) 2005; 75 Kirby (10.1016/S0140-6736(17)31145-5_bib28) 2010; 96 Hickey (10.1016/S0140-6736(17)31145-5_bib37) 2016; 7 Gentilini (10.1016/S0140-6736(17)31145-5_bib29) 2017; 122 |
| References_xml | – volume: 20 start-page: 497 year: 2008 end-page: 501 ident: bib22 article-title: Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer publication-title: Clin Oncol contributor: fullname: Broad – volume: 387 start-page: 229 year: 2016 end-page: 238 ident: bib18 article-title: 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial publication-title: Lancet contributor: fullname: Hildebrandt – volume: 51 start-page: 451 year: 2015 end-page: 463 ident: bib24 article-title: Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial publication-title: Eur J Cancer contributor: fullname: Marrazzo – volume: 12 start-page: 267 year: 2013 end-page: 277 ident: bib10 article-title: The American Brachytherapy Society consensus statement for accelerated partial breast irradiation publication-title: Brachytherapy contributor: fullname: Patel – volume: 189 start-page: 825 year: 2013 end-page: 833 ident: bib3 article-title: DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer publication-title: Strahlenther Onkol contributor: fullname: Budach – volume: 14 start-page: 1086 year: 2013 end-page: 1094 ident: bib19 article-title: The UK Standardisation of Breast Radiotherapy (START) randomised trials of radiotherapy hypofractionation for treatment of early breast cancer; 10-year follow-up results (CRUK/96/001) publication-title: Lancet Oncol contributor: fullname: Dewar – volume: 94 start-page: 264 year: 2010 end-page: 273 ident: bib8 article-title: Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009) publication-title: Radiother Oncol contributor: fullname: Pötter – volume: 86 start-page: 84 year: 1999 end-page: 87 ident: bib12 article-title: Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery publication-title: Br J Surg contributor: fullname: Miceli – volume: 39 start-page: 5814 year: 2012 end-page: 5824 ident: bib27 article-title: Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer publication-title: Med Phys contributor: fullname: Evans – volume: 26 start-page: 529 year: 2015 end-page: 535 ident: bib4 article-title: Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey publication-title: Ann Oncol contributor: fullname: Poortmans – volume: 25 start-page: 215 year: 2013 ident: bib15 article-title: Intensity-modulated radiotherapy for the treatment of breast cancer publication-title: Clin Oncol contributor: fullname: Yarnold – volume: 114 start-page: 42 year: 2015 end-page: 49 ident: bib17 article-title: Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials publication-title: Radiother Oncol contributor: fullname: Riera – volume: 373 start-page: 307 year: 2015 end-page: 316 ident: bib35 article-title: Regional nodal irradiation in early-stage breast cancer publication-title: N Engl J Med contributor: fullname: Parulekar – volume: 73 start-page: 958 year: 2009 end-page: 966 ident: bib14 article-title: Characterization of target volume changes during breast radiotherapy using implanted fiducial markers and portal imaging publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Evans – volume: 264 start-page: 413 year: 2016 end-page: 420 ident: bib33 article-title: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (alliance) ACOSOG Z0011 Randomized Trial publication-title: Ann Surg contributor: fullname: McCall – volume: 96 start-page: 178 year: 2010 end-page: 184 ident: bib28 article-title: Prone versus supine positioning for whole and partial-breast radiotherapy: a comparison of non-target tissue dosimetry publication-title: Radiother Oncol contributor: fullname: Yarnold – volume: 21 start-page: 55 year: 2011 end-page: 65 ident: bib16 article-title: Altered fractionation: rationale and justification for whole and partial breast hypofractionated radiotherapy publication-title: Semin Radiat Oncol contributor: fullname: Vicini – volume: 31 start-page: 4038 year: 2013 end-page: 4045 ident: bib25 article-title: Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy publication-title: J Clin Oncol contributor: fullname: Parpia – volume: 7 year: 2016 ident: bib37 article-title: Partial breast irradiation for early breast cancer publication-title: Cochrane Database Syst Rev contributor: fullname: See – year: 2017 ident: bib32 article-title: Development of postoperative radiotherapy for breast cancer: UK consensus statements—a model of patient, clinical and commissioner engagement? publication-title: Clin Oncol contributor: fullname: Bloomfield – volume: 39 start-page: 1179 year: 2013 end-page: 1185 ident: bib20 article-title: Use of boost radiotherapy in oncoplastic breast-conserving surgery—a systematic review publication-title: Eur J Surg Oncol contributor: fullname: Doughty – volume: 158 start-page: S35 year: 1998 end-page: S42 ident: bib2 article-title: The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists publication-title: CMAJ – volume: 74 start-page: 987 year: 2009 end-page: 1001 ident: bib6 article-title: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Buchholz – volume: 14 start-page: 297 year: 2013 end-page: 305 ident: bib34 article-title: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial publication-title: Lancet Oncol contributor: fullname: Zurrida – volume: 59 start-page: 736 year: 2015 end-page: 742 ident: bib5 article-title: Australian survey on current practices for breast radiotherapy publication-title: J Med Imaging Radiat Oncol contributor: fullname: Batumalai – volume: 90 start-page: 14 year: 2009 end-page: 22 ident: bib11 article-title: Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? publication-title: Radiother Oncol contributor: fullname: Yarnold – volume: 383 start-page: 603 year: 2014 end-page: 613 ident: bib31 article-title: Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial publication-title: Lancet contributor: fullname: Bulsara – volume: 14 start-page: 1269 year: 2013 end-page: 1277 ident: bib23 article-title: Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial publication-title: Lancet Oncol contributor: fullname: Maisonneuve – volume: 75 start-page: 9 year: 2005 end-page: 17 ident: bib21 article-title: Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial publication-title: Radiother Oncol contributor: fullname: Bliss – volume: 378 start-page: 1707 year: 2011 end-page: 1716 ident: bib1 article-title: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials publication-title: Lancet – volume: 94 start-page: 274 year: 2010 end-page: 279 ident: bib7 article-title: Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study publication-title: Radiother Oncol contributor: fullname: Fodor – volume: 373 start-page: 317 year: 2015 end-page: 327 ident: bib36 article-title: Internal mammary and medial supraclavicular irradiation in breast cancer publication-title: N Engl J Med contributor: fullname: Kirkove – volume: 85 start-page: 1179 year: 2013 end-page: 1185 ident: bib9 article-title: Evaluation of current consensus statement recommendations for accelerated partial breast irradiation: a pooled analysis of William Beaumont Hospital and American Society of Breast Surgeon MammoSite Registry Trial Data publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Shah – volume: 31 start-page: 4488 year: 2013 end-page: 4495 ident: bib30 article-title: Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis publication-title: J Clin Oncol contributor: fullname: Wilkinson – volume: 28 start-page: 345 year: 2016 end-page: 353 ident: bib26 article-title: Do patient-reported outcome measures agree with clinical and photographic assessments of normal tissue effects after breast radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) trials in early breast cancer publication-title: Clin Oncol contributor: fullname: Yarnold – volume: 35 start-page: 578 year: 2009 end-page: 582 ident: bib13 article-title: Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group publication-title: Eur J Surg Oncol contributor: fullname: Cumming – volume: 122 start-page: 37 year: 2017 end-page: 44 ident: bib29 article-title: Ipsilateral axillary recurrence after breast conservative surgery: the protective effect of whole breast radiotherapy publication-title: Radiother Oncol contributor: fullname: Leonardi – volume: 373 start-page: 317 year: 2015 ident: 10.1016/S0140-6736(17)31145-5_bib36 article-title: Internal mammary and medial supraclavicular irradiation in breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1415369 contributor: fullname: Poortmans – volume: 122 start-page: 37 year: 2017 ident: 10.1016/S0140-6736(17)31145-5_bib29 article-title: Ipsilateral axillary recurrence after breast conservative surgery: the protective effect of whole breast radiotherapy publication-title: Radiother Oncol doi: 10.1016/j.radonc.2016.12.021 contributor: fullname: Gentilini – year: 2017 ident: 10.1016/S0140-6736(17)31145-5_bib32 article-title: Development of postoperative radiotherapy for breast cancer: UK consensus statements—a model of patient, clinical and commissioner engagement? publication-title: Clin Oncol doi: 10.1016/j.clon.2017.06.011 contributor: fullname: Bloomfield – volume: 264 start-page: 413 year: 2016 ident: 10.1016/S0140-6736(17)31145-5_bib33 publication-title: Ann Surg doi: 10.1097/SLA.0000000000001863 contributor: fullname: Giuliano – volume: 14 start-page: 297 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib34 article-title: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70035-4 contributor: fullname: Galimberti – volume: 31 start-page: 4488 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib30 article-title: Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis publication-title: J Clin Oncol doi: 10.1200/JCO.2013.49.7842 contributor: fullname: Mukesh – volume: 35 start-page: 578 year: 2009 ident: 10.1016/S0140-6736(17)31145-5_bib13 article-title: Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2008.09.005 contributor: fullname: Coles – volume: 373 start-page: 307 year: 2015 ident: 10.1016/S0140-6736(17)31145-5_bib35 article-title: Regional nodal irradiation in early-stage breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1415340 contributor: fullname: Whelan – volume: 14 start-page: 1269 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib23 article-title: Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70497-2 contributor: fullname: Veronesi – volume: 14 start-page: 1086 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib19 article-title: The UK Standardisation of Breast Radiotherapy (START) randomised trials of radiotherapy hypofractionation for treatment of early breast cancer; 10-year follow-up results (CRUK/96/001) publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70386-3 contributor: fullname: Haviland – volume: 96 start-page: 178 year: 2010 ident: 10.1016/S0140-6736(17)31145-5_bib28 article-title: Prone versus supine positioning for whole and partial-breast radiotherapy: a comparison of non-target tissue dosimetry publication-title: Radiother Oncol doi: 10.1016/j.radonc.2010.05.014 contributor: fullname: Kirby – volume: 39 start-page: 5814 year: 2012 ident: 10.1016/S0140-6736(17)31145-5_bib27 article-title: Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer publication-title: Med Phys doi: 10.1118/1.4748332 contributor: fullname: Donovan – volume: 26 start-page: 529 year: 2015 ident: 10.1016/S0140-6736(17)31145-5_bib4 article-title: Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey publication-title: Ann Oncol doi: 10.1093/annonc/mdu561 contributor: fullname: Belkacemi – volume: 189 start-page: 825 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib3 article-title: DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer publication-title: Strahlenther Onkol doi: 10.1007/s00066-013-0437-8 contributor: fullname: Sedlmayer – volume: 12 start-page: 267 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib10 article-title: The American Brachytherapy Society consensus statement for accelerated partial breast irradiation publication-title: Brachytherapy doi: 10.1016/j.brachy.2013.02.001 contributor: fullname: Shah – volume: 86 start-page: 84 year: 1999 ident: 10.1016/S0140-6736(17)31145-5_bib12 article-title: Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery publication-title: Br J Surg doi: 10.1046/j.1365-2168.1999.00961.x contributor: fullname: Salvadori – volume: 7 year: 2016 ident: 10.1016/S0140-6736(17)31145-5_bib37 article-title: Partial breast irradiation for early breast cancer publication-title: Cochrane Database Syst Rev contributor: fullname: Hickey – volume: 31 start-page: 4038 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib25 article-title: Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2013.50.5511 contributor: fullname: Olivotto – volume: 383 start-page: 603 year: 2014 ident: 10.1016/S0140-6736(17)31145-5_bib31 article-title: Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(13)61950-9 contributor: fullname: Vaidya – volume: 387 start-page: 229 year: 2016 ident: 10.1016/S0140-6736(17)31145-5_bib18 publication-title: Lancet doi: 10.1016/S0140-6736(15)00471-7 contributor: fullname: Strnad – volume: 28 start-page: 345 year: 2016 ident: 10.1016/S0140-6736(17)31145-5_bib26 article-title: Do patient-reported outcome measures agree with clinical and photographic assessments of normal tissue effects after breast radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) trials in early breast cancer publication-title: Clin Oncol doi: 10.1016/j.clon.2016.01.011 contributor: fullname: Haviland – volume: 75 start-page: 9 year: 2005 ident: 10.1016/S0140-6736(17)31145-5_bib21 article-title: Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial publication-title: Radiother Oncol doi: 10.1016/j.radonc.2005.01.005 contributor: fullname: Yarnold – volume: 25 start-page: 215 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib15 article-title: Intensity-modulated radiotherapy for the treatment of breast cancer publication-title: Clin Oncol doi: 10.1016/j.clon.2012.11.003 contributor: fullname: Coles – volume: 21 start-page: 55 year: 2011 ident: 10.1016/S0140-6736(17)31145-5_bib16 article-title: Altered fractionation: rationale and justification for whole and partial breast hypofractionated radiotherapy publication-title: Semin Radiat Oncol doi: 10.1016/j.semradonc.2010.08.007 contributor: fullname: Théberge – volume: 85 start-page: 1179 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib9 article-title: Evaluation of current consensus statement recommendations for accelerated partial breast irradiation: a pooled analysis of William Beaumont Hospital and American Society of Breast Surgeon MammoSite Registry Trial Data publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2012.10.010 contributor: fullname: Wilkinson – volume: 158 start-page: S35 issue: suppl 3 year: 1998 ident: 10.1016/S0140-6736(17)31145-5_bib2 article-title: The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists publication-title: CMAJ – volume: 378 start-page: 1707 year: 2011 ident: 10.1016/S0140-6736(17)31145-5_bib1 article-title: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(11)61629-2 – volume: 114 start-page: 42 year: 2015 ident: 10.1016/S0140-6736(17)31145-5_bib17 article-title: Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials publication-title: Radiother Oncol doi: 10.1016/j.radonc.2014.11.014 contributor: fullname: Marta – volume: 51 start-page: 451 year: 2015 ident: 10.1016/S0140-6736(17)31145-5_bib24 article-title: Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial publication-title: Eur J Cancer doi: 10.1016/j.ejca.2014.12.013 contributor: fullname: Livi – volume: 59 start-page: 736 year: 2015 ident: 10.1016/S0140-6736(17)31145-5_bib5 article-title: Australian survey on current practices for breast radiotherapy publication-title: J Med Imaging Radiat Oncol doi: 10.1111/1754-9485.12348 contributor: fullname: Dundas – volume: 20 start-page: 497 year: 2008 ident: 10.1016/S0140-6736(17)31145-5_bib22 article-title: Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer publication-title: Clin Oncol doi: 10.1016/j.clon.2008.03.017 contributor: fullname: Haviland – volume: 74 start-page: 987 year: 2009 ident: 10.1016/S0140-6736(17)31145-5_bib6 article-title: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2009.02.031 contributor: fullname: Smith – volume: 90 start-page: 14 year: 2009 ident: 10.1016/S0140-6736(17)31145-5_bib11 article-title: Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? publication-title: Radiother Oncol doi: 10.1016/j.radonc.2008.05.002 contributor: fullname: Mannino – volume: 94 start-page: 264 year: 2010 ident: 10.1016/S0140-6736(17)31145-5_bib8 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2010.01.014 contributor: fullname: Polgár – volume: 94 start-page: 274 year: 2010 ident: 10.1016/S0140-6736(17)31145-5_bib7 article-title: Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study publication-title: Radiother Oncol doi: 10.1016/j.radonc.2010.01.019 contributor: fullname: Polgár – volume: 73 start-page: 958 year: 2009 ident: 10.1016/S0140-6736(17)31145-5_bib14 article-title: Characterization of target volume changes during breast radiotherapy using implanted fiducial markers and portal imaging publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2008.10.030 contributor: fullname: Harris – volume: 39 start-page: 1179 year: 2013 ident: 10.1016/S0140-6736(17)31145-5_bib20 article-title: Use of boost radiotherapy in oncoplastic breast-conserving surgery—a systematic review publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2013.07.240 contributor: fullname: Schaverien |
| SSID | ssj0004605 |
| Score | 2.689717 |
| Snippet | Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and... A comprehensive literature search using PubMed and MEDLINE was done before the trial opened to identify all previous pathological and clinical breast... |
| SourceID | pubmedcentral proquest crossref pubmed elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 1048 |
| SubjectTerms | Breast - pathology Breast cancer Breast Neoplasms - pathology Breast Neoplasms - radiotherapy Breast Neoplasms - surgery Cancer Cancer therapies Carcinoma, Ductal - pathology Carcinoma, Ductal - radiotherapy Carcinoma, Ductal - surgery Clinical trials Evidence-based medicine Female Humans Mastectomy Mastectomy, Segmental - methods Metastasis Middle Aged Neoplasm Recurrence, Local - prevention & control Neoplasm Staging Patients Radiation therapy Radiotherapy Dosage Surgery Survival analysis Treatment Outcome Tumors United Kingdom |
| Title | Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial |
| URI | https://dx.doi.org/10.1016/S0140-6736(17)31145-5 https://www.ncbi.nlm.nih.gov/pubmed/28779963 https://www.proquest.com/docview/1937767688/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC5594247 |
| Volume | 390 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9swDBb6AIZdhr2btSt42KEFosWWpcjeZdiKFtkjbdA1WG6GLMtogMBJE_fQ_7kfNNKW03XrtovhlywbosWP4keSsTdB5JxMioibxARc2jjhRqiYF0ZQ5GchbJ2nYHjaH4zl54mabLBBGwtDtMp2Tqwn6nxuaY28h0CDEs_00WAzGa0C2Kr3fnHFqX4U-Vl9MY1Nti1CSQ7b7Y_Hp6Pz-2Ika7r7bTRP79v65EGoDyO0EBRXf9NTf-LQ3-mUv-ink8fskQeW8KGRhCdsw5VP2YOhd50_Yz9GJCRmxjOioVewNPnUR1_dQF0pHPwVSwRrv1QLqyZsGhDbgs_BugJavAVHqZHXbUh4lnAw_gKfhqOz8wv4evYd6pIgh-9A8Ru8G9Cyv55hcwppAQM1l7H-GtfF1ynzOcqcy7vg6fMz2l9copqFqAvlvOTEHFtO51Rvr3n2czY-Ob44GnBf0oFbJXXFXZGFgQtc0S_In5qF1tocLURlpEkSZ0VsDB7pXEYyizKlhXVhHBSFdbEwgYtesC3sz-0wQOgW5Mq5mErWmEiaOBdaucgZVD9C2g572w5gumgyd6T3UNpCndYjnqoOi9thTj38aGBFitrlf033WrFI_RywSm8ltsNeNhKyfhG0UzVamlGH6Tuys76Bsn7fvVJOL-vs32gCSiH1q393ucseCgIg5PpK9thWtbx2rxE-Vdk-29QTjdv4KNz3f8lPYqgdpQ |
| link.rule.ids | 230,315,786,790,891,12083,12250,21416,27957,27958,31754,33301,33779,43345,43614,43840,74102,74371,74659 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELdgSMDLxOcoDLgHHjapZok_GocXhCamjrXbBK3YW-Q4jlapakvbPez_3B_EneN2DAa8JbEdO_I59zv7d3eMvUuk9yqvJbe5TbhyJudWaMNrK8jzsxYuxCnoH3e6Q_XlTJ_FDbdFpFWu_onhR11NHe2R7yHQoMAzHWM-zn5wyhpFp6sxhcZddk9JVDTkKb6f3uYXGSju1x48e9_WD3fSbFeiVaC5_ptu-hN7_k6h_EUnHTximxFMwqdm9h-zO37yhN3vx-Pyp-zqlATDjnlJ1PMlzG01ih5XlxCyg0MscUSqjtuzsGhcpQHxLMS4qwugDVvwFA553YYEZg47wyM47J-efB1A7-Q7hDQgux9A80usDWjNX4yxObmxgIXAXwxf49s4nEk1RTnzVRsiZX5M17NzVK0g2zCZTjixxeajKeXYa979jA0PPg_2uzymceBOq2zJfV2miU983anpDLVMnXMVWoXaKpvn3gljLd5llZKqlKXOhPOpSeraeSNs4uVztoH9-RcMEK4llfbeUJoaK5U1lci0l96iyhHKtdj71QQWsyZaR3ELjS3NijDjhW4xs5rmIkKOBkoUqFH-13R7JRZFXPeL4lpKW2yrkZD1QNA2zdC6lC2W3ZCddQWK9H2zZDI6DxG_0exTQmUv_93lW_agO-j3it7h8dEr9lAQAKGjr3ybbSznF_41wqdl-SaskZ8YrxmJ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9NAEF5BK1VcEO-GFpgDh1bKUnsfWZsL4tGopU0alUb0Zq3XazVS5KRJeuj_5AcxY29SCgVufq0f2s873-x-M8PY20h6r9JScpvaiCuXpNwKnfDSCor8LIWr8xT0-p2Dofp6rs-D_mkeZJXLMbEeqIuJoznyPSQalHimgw5bGWQRgy_dD9NLThWkaKU1lNO4z9aN6mhE-Pqn_f7g9K4oyVrwfhPPs_dtdXAnNrsSfQTN9d8s1Z9M9HdB5S8WqvuIPQzUEj42WHjM7vnqCdvohcXzp-zHgGBixzwnIfoCZrYYhfira6hrhUM440hiHSZrYd4ETgOyWwhZWOdA07fgKTnyqg3BZwY7wyM47A1OTs_g-OQ71EVBdt-D5td4NaBvfzXG5hTUAhZqNWP9Nb6Nr1MVE0SdL9oQBPRj2p5eoKEF2YZqUnHSjs1GE6q419z7GRt2988-H_BQ1IE7rcyC-zKPIx_5slPSimoeO-cK9BG1VTZNvROJtbhnCiVVLnNthPNxEpWl84mwkZfP2Ro-z28yQPIWFdr7hIrWWKlsUgijvfQWDZBQrsXeLTswmza5O7I7RG2xyeoez3SLJctuzgIBaYhFhvblf023l7DIwigwz24w22IvGoSsXgQ9VYO-pmwxcws7qwso7_ftM9Xoos7_jU6gEsq8_Pcj37AN_EGy48P-0RZ7IIiN0DpYus3WFrMr_wq51CJ_HX6Sn32QH2E |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Partial-breast+radiotherapy+after+breast+conservation+surgery+for+patients+with+early+breast+cancer+%28UK+IMPORT+LOW+trial%29%3A+5-year+results+from+a+multicentre%2C+randomised%2C+controlled%2C+phase+3%2C+non-inferiority+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Coles%2C+Charlotte+E&rft.au=Griffin%2C+Clare+L&rft.au=Kirby%2C+Anna+M&rft.au=Titley%2C+Jenny&rft.date=2017-09-09&rft.eissn=1474-547X&rft.volume=390&rft.issue=10099&rft.spage=1048&rft_id=info:doi/10.1016%2FS0140-6736%2817%2931145-5&rft_id=info%3Apmid%2F28779963&rft.externalDocID=28779963 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |